You are here

FDA Approves Brimonidine Tartrate, Glaucoma Treatment

FORT WORTH, Texas, Sept. 16 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration today approved Falcon Pharmaceuticals, Ltd.'s (Falcon) generic brimonidine tartrate ophthalmic solution 0.2% (brimonidine). Falcon is an affiliate of Alcon, Inc. , the world's leading eye care company. Brimonidine is therapeutically equivalent to Alphagan* and is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The drug is available immediately, and comes in a Drop-tainer** dispenser in three sizes: 5mL, 10mL and 15mL. At the time of manufacture, the product will have a 24-month shelf life.

Although Falcon's marketing and sales efforts will target wholesale distributors, retail pharmacies, hospitals and managed care organizations, it will also communicate the availability of brimonidine directly to ophthalmologists.

Falcon is the largest manufacturer and marketer of generic drugs for the eye and ear in the United States. Alcon is the world's leading eye care company and has been dedicated to the ophthalmic industry for more than 50 years. It develops, manufactures and markets the widest selection of pharmaceuticals, surgical products, contact lens solutions and other vision care products that treat diseases, disorders and other conditions of the eye.

Source: Alcon, Inc.

Recent Headlines

Over Half of Patients Had Reduced Pain Levels of 30% or More
Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
Over 25% of Study Patients Showed 6–12 Months Remission
Researchers Extend Previous Data, Find Association is Reversed
First Anti-PD-1 Therapy Demonstrates Improved Overall Survival
New Test Could Prevent Short- and Long-term Complications